FDA approves Alecensa for ALK-positive early-stage lung cancer – The Cancer Letter
FDA approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. […]